Royal Philips: Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis

June 30, 2022Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis

Related Keywords

Washington ,District Of Columbia ,United States ,Netherlands ,Amsterdam ,Noord Holland ,Scott Hutton ,Philips Oncologyto ,Kathy Oreilly ,International Agency For Research On Cancer ,Philips Global Press Office ,Twitter ,World Health Organization ,Genscript Inc ,Philips ,International Early Lung Cancer Action Program Investigators ,Philips Lung Cancer Orchestrator ,Cancer Orchestratorlung ,Biodesix Nodify Lung ,Lung Cancer ,Chief Executive Officer ,Lung Cancer Orchestrator ,Cancer Orchestratoris ,World Health ,Early Lung Cancer Action Program ,Nodify Lung ,Diagnostic Cortex ,Artificial Intelligence ,Pass Neutralization Test Kit ,Cancer Orchestrator ,Royal ,Incorporates ,Biodesix ,Flood ,Ased ,Roteomic ,Module ,Risk ,Assessment ,Testing ,Young ,Dancer ,Orchestrator ,Advance ,Early ,Diagnosis ,